Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Quest Diagnostics Receives New York State Approval for Haystack MRD Test

4 September 2026 · By · Wire by Fusion42

Published

4 September 2026

Topic

opportunities

◆ Sectors

Diagnostics

◆ Geography

United States

◆ Source

Read at genomeweb.com →

◆ Verified

Fusion42 · 4 September 2026 · Fusion42 review

Quest Diagnostics has obtained New York State Department of Health approval for its Haystack MRD test, allowing its use to detect minimal residual disease in patients with various solid tumors.

This Wire brief sits within Fusion42's coverage of Diagnostics.

◆ ◆ The Wire takeaway

You can now offer your cancer patients in New York access to an approved test that detects disease persistence after treatment. This opens a regulatory door that could accelerate patient adoption and payor interest.

◆ Coverage

1 source · 4 Sep 2026

◆ Related on Wire

◆ Topics

DiagnosticsMRD-testingdiagnosticsregulatory-approvalcancer-testing